SpringWorks Therapeutics (Nasdaq: SWTX) is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer.
SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates. Its lead pipeline programs are in potentially registrational clinical trials for rare oncology indications. Nirogacestat, a gamma secretase inhibitor, is in a Phase 3 clinical trial for the treatment of desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors. There are currently no approved therapies for patients with desmoid tumors. Mirdametinib, a MEK inhibitor, is in a Phase 2b clinical trial for the treatment of adults and children with neurofibromatosis type 1-associated plexiform neurofibromas, which are peripheral nerve sheath tumors that cause severe pain, disfigurement and a shortened life span.
SpringWorks was founded in 2017 by Bain Capital Life Sciences, Bain Capital Double Impact, and OrbiMed in partnership with Pfizer to advance a portfolio of four clinical stage assets targeting areas of significant unmet medical need. Bain Capital Life Sciences continues to be an active member of the Company’s Board of Directors.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.